Premium
WONOEP appraisal: Development of epilepsy biomarkers—What we can learn from our patients?
Author(s) -
Jozwiak Sergiusz,
Becker Albert,
Cepeda Carlos,
Engel Jerome,
Gnatkovsky Vadym,
Huberfeld Gilles,
Kaya Mehmet,
Kobow Katja,
Simonato Michele,
Loeb Jeffrey A.
Publication year - 2017
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.13728
Subject(s) - epileptogenesis , epilepsy , disease , medicine , biomarker , intensive care medicine , clinical trial , bioinformatics , psychiatry , biochemistry , chemistry , biology
Summary Objective Current medications for patients with epilepsy work in only two of three patients. For those medications that do work, they only suppress seizures. They treat the symptoms, but do not modify the underlying disease, forcing patients to take these drugs with significant side effects, often for the rest of their lives. A major limitation in our ability to advance new therapeutics that permanently prevent, reduce the frequency of, or cure epilepsy comes from a lack of understanding of the disease coupled with a lack of reliable biomarkers that can predict who has or who will get epilepsy. Methods The main goal of this report is to present a number of approaches for identifying reliable biomarkers from observing patients with brain disorders that have a high probability of producing epilepsy. Results A given biomarker, or more likely a profile of biomarkers, will have both a quantity and a time course during epileptogenesis that can be used to predict who will get the disease, to confirm epilepsy as a diagnosis, to identify coexisting pathologies, and to monitor the course of treatments. Significance Additional studies in patients and animal models could identify common and clinically valuable biomarkers to successfully translate animal studies into new and effective clinical trials.